Life sciences briefing: Friday, Oct. 5, 2007

Featured companies: Gilde Healthcare Partners, Konanda Pharma Partners, Healthvision, OrbiMed, Quovadx, Serentis, Surface, Visiopharm

Danish microscopy company Visiopharm gets funding — Copenhagen’s Visiopharm, a developer of image-analysis hardware and software for microscopy, raised an undisclosed sum from Northcap Partners. The …

Life sciences briefing: Thursday, Oct. 4, 2007

Featured companies: 23andMe, APT Pharmaceuticals, Hyperion Therapeutics, Isis Biopolymer, Virogenomics

UPDATED at 10:30am PT.

APT Pharma raises $22M for transplant and heart drugs — Burlingame, Calif.’s APT Pharmaceuticals, a specialty pharma currently focused on a drug to fight organ-transplant rejection, …

Life sciences briefing: Wednesday, Oct. 3, 2007

Featured companies: Aveo Pharmaceuticals, Aviir, deltaDot, Origen Therapeutics

Heart-diagnostic maker Aviir raises $11.3M — Palo Alto, Calif.-based Aviir, a biotech developing cardiovascular diagnostics based on Stanford research, raised $11.3 million of an expected $25 million second funding round, PE Hub …

Life sciences briefing: Tuesday, Oct. 2, 2007

Featured companies: Change:healthcare, Gemin X Biotechnologies, Ipsogen, the Practice

Change:healthcare raises $1M for health 2.0 sites — Nashville, Tenn.-based change:healthcare, a provider of Web-based health information, raised $1 million in a first funding round. The investment firm Solidus, also based …

Life sciences briefing: Monday, Oct. 1, 2007

Featured companies: Abiant, CellXplore, Diffusion Pharmaceuticals, WMR Biomedical, Zosano Pharmaceuticals

Diffusion Pharma raises $4.5M for vascular-disease and brain-cancer drug — Charlottesville, Va.-based Diffusion Pharmaceuticals, a biotech focused on drugs that enhance oxygen diffusion, raised $4.5 million in a private placement. …

Life sciences briefing: Friday, Sept. 28, 2007

Featured companies: Imalux, Sagent Pharmaceuticals, Sequel Pharmaceuticals, Sinexus, TranS1, U.S. Spinal Technologies

Sagent Pharmaceuticals draws in $53M for injectable generics — Sagent Pharmaceuticals, proving that there’s still life in the apparently lucrative but boring specialty-pharmaceuticals business, raised $53 million in …